PERRIGO Co plc (PRGO) Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Perrigo Company plc NYSE:PRGO Healthcare · Drug Manufacturers - Specialty & Generic
Mkt Cap $2.2B
Div Yield 7.32%
CLOSED · Nov 6 $15.85 CLOSED · Nov 6 Prev close $15.71 Close $15.85 0.00% AH close $15.85 VOL 2.31M $ Vol $36.56M RVOL 0.93x
Mkt Cap $2.2B
VOL 2.31M sh
$ Vol $36.56M
RVOL 0.93×
Div Yield 7.32%
Press Release ● Major ⚠ 6
Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations
Perrigo reported 3Q26 net sales of $989 million from continuing operations, down 5.2% year-over-year, with reported diluted EPS of $(0.10) versus $0.09 a year ago.
Core adjusted EPS fell 9.0% to $0.61 and All In adjusted EPS dropped 25.0% to $0.60, as lower consumption, cautious retailer inventory positioning, and European softness outweighed share gains in U.S. store brand OTC.
The company cut its FY26 Core adjusted EPS outlook to $2.15-$2.35 from $2.25-$2.55 and lowered Core net sales growth guidance to (3.6)% to (2.5)%.
The Infant Formula divestiture for up to $175 million will simplify the portfolio but will trigger an expected impairment loss of $275-$375 million in Q4, and the Oral Care strategic review remains ongoing.
• 4d ago AI analysis › Press Release
Perrigo Announces Quarterly Dividend
Perrigo declared a quarterly dividend of $0.29 per share, or $1.16 annualized.
The dividend is payable December 15, 2026, to shareholders of record on November 27, 2026.
The declaration maintains the existing payout with no change in rate and carries no new financial disclosure.
• 10d ago AI analysis › Press Release ● Major ⚠ 4
Perrigo Announces Agreement to Divest Infant Formula Business to MeridianMade
Perrigo has agreed to divest its Infant Formula business to MeridianMade for total consideration of up to $175 million — $40 million cash at closing plus up to $135 million contingent on milestones through 2030.
The sale advances the Streamline pillar of Perrigo's Three-S plan and is expected to enhance margins and materially reduce future capital expenditures. The divested business generated $380 million in trailing-four-quarter net sales but only $8 million in segment adjusted operating income.
Perrigo expects to record a non-cash impairment of $275-$375 million in Q4 2026, with Infant Formula moving to discontinued operations from that quarter. Closing is expected in the first half of 2027, subject to regulatory approvals.
• 10d ago AI analysis › Press Release ⚠ 1
Perrigo to Release Third Quarter 2026 Financial Results on November 4, 2026
Perrigo announced it will release third quarter 2026 financial results on Wednesday, November 4, 2026, with a conference call at 8:30 a.m. ET.
The call will be hosted by Interim President and CEO Albert Manzone and CFO Eduardo Bezerra, with a live webcast and replay available through November 11.
This is a routine scheduling notice with no financial results; note the company is still led by an interim CEO.
• 18d ago AI analysis › Press Release
Perrigo to Attend the Barclays Global Consumer Conference
Perrigo executives Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Barclays Global Consumer Conference.
The event is set for Thursday, September 10, 2026, offering an opportunity for management to engage with the investment community.
No specific presentation materials or new financial guidance were provided in the release.
• 2mo ago AI analysis › Press Release ⚠ 3
Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations
Perrigo reported Q2 2026 net sales of $1.02 billion, down 3.2% year-over-year, while reported diluted EPS rose to $0.63 from $0.00 in the prior year due to a gain on the Dermacosmetics divestiture.
Underlying business performance was softer, with adjusted EPS declining 12.3% to $0.50 and core revenue falling 3.1% amid ongoing category softness and unfavorable mix.
Management reaffirmed its full-year 2026 outlook for adjusted EPS of $2.00 to $2.30, expecting a sequentially stronger second half driven by operational execution and easing under absorption.
• 3mo ago AI analysis › Press Release
Perrigo Announces Quarterly Dividend
Perrigo's Board of Directors declared a quarterly dividend of $0.29 per share, representing an annualized rate of $1.16.
The dividend is payable on September 15, 2026 to shareholders of record at the close of business on August 28, 2026.
The company continues to focus on its pure-play self-care model, leveraging store brand cash flow to support branded products like Opill and Mederma.
• 3mo ago AI analysis › Press Release
Perrigo to Present at the Canaccord 46th Annual Growth Conference
Perrigo executives are scheduled to present at the Canaccord 46th Annual Growth Conference.
Interim President and CEO Albert Manzone and CFO Eduardo Bezerra will present on Wednesday, August 12th at 10:30 AM EDT.
The webcast will be available on the Perrigo investor relations website.
• 3mo ago AI analysis › Press Release
Perrigo to Release Second Quarter 2026 Financial Results on August 5, 2026
Perrigo Company plc announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026.
The company will host a conference call at 8:30 a.m. EST to discuss the results, hosted by Interim President and CEO Albert Manzone and CFO Eduardo Bezerra.
A live webcast will be available on the Perrigo investor relations website, with a replay accessible until August 12.
• 3mo ago AI analysis › Press Release
Perrigo Announces Appointment of Two New Independent Directors to Board
Perrigo appointed Salman Amin and Omer Gajial as independent directors to its Board, effective June 30, 2026.
Mr. Amin brings over 30 years of experience, most recently as CEO of pladis Global and previously at SC Johnson, PepsiCo, and Procter & Gamble.
Mr. Gajial currently serves as CEO of GoTo Foods and was formerly Executive Vice President at Albertsons Companies.
• 4mo ago AI analysis › Press Release
Perrigo Announces Leadership Transition
Albert A. Manzone, a current director at Syntec Optics Holdings, has been appointed Interim President and CEO of Perrigo Company plc.
He succeeds Patrick Lockwood-Taylor, who resigned immediately following a board determination that his personal conduct was inconsistent with the Company's Code of Conduct, though unrelated to business operations.
Perrigo's board has initiated a comprehensive search for a permanent successor while reaffirming its full-year 2026 financial outlook.
• 5mo ago AI analysis › Press Release
Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference
Perrigo Company plc announced that CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference.
The presentation is scheduled for Tuesday, June 9th at 10:30 AM EDT and will be available via webcast on the company's investor relations website.
This is a standard investor relations calendar update with no new operational or financial disclosures.
• 5mo ago AI analysis › Press Release ⚠ 3
Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations
Perrigo reported Q1 Core adjusted EPS of $0.40, topping expectations, while total revenue declined 7.2% year-over-year to $969 million.
Results were weighed down by a non-cash goodwill impairment charge of $330.8 million and lower consumption across U.S. and European markets, though Specialty Care segment sales grew.
The company maintained its full-year 2026 outlook and completed the sale of its Dermacosmetics business for roughly €306 million in upfront cash to reduce debt.
• 6mo ago AI analysis › Press Release ● Major
Perrigo Completes Divestiture of Dermacosmetics Business
Perrigo completed the sale of its Dermacosmetics business to Karo Healthcare for €305.6 million upfront, plus up to €27 million in milestone payments.
The divested unit generated approximately €120 million in net sales in 2025 and represented 5% of adjusted operating income.
Net proceeds will be used primarily to reduce debt, advancing the company's 'Three-S plan' to streamline its portfolio.
• 6mo ago AI analysis › Press Release
Perrigo Announces Quarterly Dividend
Perrigo's Board of Directors declared a quarterly dividend of $0.29 per share, which equates to an annualized rate of $1.16 per share.
The dividend is payable on June 16, 2026, to shareholders of record as of the close of business on May 29, 2026.
• 6mo ago AI analysis › Press Release
Perrigo to Release First Quarter 2026 Financial Results on May 6, 2026
prnewswire.com • 6mo ago 
